Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Haier Smart Home Sees Profit Drop as Revenue Grows
Trending in China: Can You Stop People Giving ‘Too Much’ Money to Their Favorite Live-Streamers?
Trending in China: Concerns Over Traditional Chinese Comedy ‘Selling Out’ In the Digital Age
ByteDance Doubles Down On Education
Chinese Biotech Firm Gracell Nets $100m From Wellington, OrbiMed, Others
Alibaba’s Hometown Could Become First in China to Issue Facial Recognition Ban
Battery and Hybrid Cars Will Dominate China’s Roads in 15 Years
Trending in China: Do The Sins Of The Father Fall On Their Sons? Social Media Lambast Pop Star with ‘Deadbeat’ Dad
Chinese Electronics Panel Maker CSOT Reports Profit Growth as Demand Soars
Xiaomi Invests in Home Improvement Firm Amid Push into Internet of Things
TikTok Escalates Patent Fight With Triller Amid Sale Talks
Chinese Self-Heating Hot Pot Brand Zihaiguo Nets Over $50m in Series C Round Led by CICC
Xiaomi Leads India’s Smartphone Market with 26.1% Share
Trending in China: Are China’s Blue-Collar Wages Really Higher Than Graduate Salaries?
Trending in China: An End to Spam Calls? Real Estate Company to Give Money to Anyone Who Receives One
Trending in China: Patriotic War Film Overpowers Foreign-Made Feature, But Not Everyone Is Impressed
Shopify Partners with TikTok to Drive Online Sales
Lawson Tests Next Step of Convenience Store Evolution in China
PUBG Creator Krafton Hires Bankers for Possible Record IPO
Mobile Browser Crackdown Ensnares Big Names
Hillhouse-Backed Genor Plans $200 Million Hong Kong IPO

By Bloomberg / Dec 13, 2019 04:36 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Genor Biopharma Co. is planning an initial public offering in Hong Kong that could raise about $200 million, according to people familiar with the matter.

The company, backed by affiliates of private equity firm Hillhouse Capital, has contacted potential advisers for the share sale, said the people, who asked not to be identified as the discussions are private. The listing could happen as soon as mid-2020, the people said.

The Shanghai-based company was seeking to raise about $100 million from private investors earlier this year to fuel growth, Bloomberg News reported in October. The Chinese drugmaker’s valuation could reach as much as $1 billion after the funding round, people familiar with the matter have said.

Details of the IPO including size and timeline could still change as deliberations continue, the people said. A representative for Genor didn’t immediately respond to requests for comment.

Founded in 2007, Genor is developing and commercializing therapeutic antibodies to fight cancer and other diseases, according to its website. It has more than 400 employees in three cities in China as well as its laboratory in the U.S. The drugmaker has more than 10 products in its pipeline with many of them in clinical development.

Share this article
Open WeChat and scan the QR code